$8.86
0.0550.62%
Últ. Act.: Oct 30, 2:40 PM
Harvard Bioscience (HBIO) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Harvard Bioscience (HBIO) publicó su última previsión de agosto 11, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $89.15M - $90.88M para el período.
En comparación con la previsión anterior, Harvard Bioscience elevado redujo su previsión de ingresos desde un rango anterior de $21M - $22.6M.
Harvard Bioscience ha emitido 16 actualizaciones de orientación entre el noviembre 8, 2022 y el agosto 11, 2026. During this period, the company raised its outlook 5 times and lowered it 7 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.15 | $-0.03 | $0.30 | $0.10 |
| Actual | $-0.14 | $-0.33 | $0.00 | $0.00 |
| Surprise | +6.67% | -1000.0% | -100.0% | -100.0% |
| Revenue | ||||
| Estimate | $21.4M | $21.2M | $23.1M | $20.0M |
| Actual | $22.7M | $20.8M | $23.7M | $20.6M |
| Surprise | +5.95% | -2.10% | +2.75% | +2.95% |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-0.10 | $0.26 |
| Revenue | ||
| Consensus | $21.8M | $24.5M |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 11, 2026 | $-0.14 | $-0.15 | 6.67 % |
| Q1 | May 12, 2026 | $-0.33 | $-0.03 | -1000.0 % |
| Q4 | Mar 12, 2026 | $0 | $0.30 | -100.0 % |
| Q3 | Nov 6, 2025 | $0 | $0.10 | -100.0 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 11, 2026 | $22.73M | $21.45M | 5.95 % |
| Q1 | May 12, 2026 | $20.76M | $21.20M | -2.10 % |
| Q4 | Mar 12, 2026 | $23.74M | $23.10M | 2.75 % |
| Q3 | Nov 6, 2025 | $20.59M | $20.00M | 2.95 % |